First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non–small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab with chemotherapy in patients with programmed death ...Leggi tutto